COVID-19 Resources for CRRT Treatment
CRRT is preferred treatment modality for COVID-19 patients with AKI
The Role of CRRT in the Fight
15-40%
of patients with COVID-19 who are admitted to the ICU have AKI requiring RRT.1-3 There is some evidence that COVID-19 interferes with kidney function itself.1
60-80%
is the mortality rate seen in patients with combined respiratory failure and AKI, indicating the consequences of AKI in mechanically ventilated patients is significant (independent mortality of AKI in the ICU is 30-50%).4
Resource Sections
Go directly to more information on the following:
CRRT Coding and Reimbursement Guide
View resourceTherapy Modalities, Comparisons, and Considerations
View resourceKDIGO Guidelines or Quick Reference
View resourcePRISMAFLEX/PRISMAX Safety Alert Regarding Modifications to Set-up
View resourcePRISMAFLEX/PRISMAX Systems Cleaning for SARS-CoV-2
View resourcePRISMAFLEX Operator’s Manual
View resourcePRISMAX Operator’s Manual
View resourceClinical Support Help-line
MD and PharmD on call at all times to help answer your questions and/or help you troubleshoot step-by-step.
888-404-ICON (4266)
Technical Support
If you need ordering or logistics support, call
888-229-0001 or online
PRISMAFLEX Rentals
For immediate rental needs, call customer service at:
800-352-1221
U.S. Medical Information
For product questions or complaints, call
888-736-2543 Option 2
The PRISMAFLEX and PRISMAX Systems are intended for: PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information Indications and Usage
|
Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information. |